Taken together, our data suggest that long term anti-angiogenic effects of TSP-2 gene therapy causing capillary rarefaction with relative ischemia and hypoxia that drives a profibrotic reaction during CAN, which may be mediated via a TGF-β independent increase of CTGF. The gene discussed is CCN2; the disease is Crouzon syndrome-acanthosis nigricans syndrome.